ProfileGDS5678 / 1441943_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 1% 3% 3% 8% 3% 2% 2% 1% 3% 6% 4% 3% 3% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.775271
GSM967853U87-EV human glioblastoma xenograft - Control 21.939373
GSM967854U87-EV human glioblastoma xenograft - Control 31.94193
GSM967855U87-EV human glioblastoma xenograft - Control 42.136628
GSM967856U87-EV human glioblastoma xenograft - Control 51.900643
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 11.912962
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.910092
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.739631
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.912483
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.123266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.979464
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.92683
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.937393
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.078915